Clinical Trials Search Results

Search for

in

Accepting Participants (3)

Showing 1-3 of 3

Sorted By:

A-Z
Z-A

Previous Next

INCB 50465-313: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kdelta Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
JCAR017-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
This study is designed to evaluate the safety and efficacy of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information.
S1803: Phase III Study of Daratumumab/rHuPH20 (NSC – 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Meyloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2.

Previous Next

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.